DR Horton (NYSE:DHI) Rating Restated
In a research note revealed to clients and investors on Monday morning, DR Horton (NYSE:DHI) stock “Outperform” was reiterated at Wedbush. They currently have a $42.0 TP on the stock. Wedbush’s TP means a potential upside of 14.44 % from the company’s close price.
NYSE:DHI is currently trading 0.01% higher at $36.70 as of 12:02 AM New York time. DR Horton’s stock is 0% over the last 200 days. It has underperformed the S&P500, which has surged 6.00% over the same time.
According to data compiled by Thomson Reuters, DR Horton (NYSE:DHI)’s stock is covered by 18 equity analysts across the Street, with 0 analysts giving it a Sell rating, 8 a Buy rating, while 12 consider it a Hold. The 12-month consensus target price for the stock is $33.61, which reflects an downside potential of 8.42% over the current price.
Element Capital Management Llc had the biggest stake with ownership of 2.02M shares as of Q2 2015 for 10.3% of the fund portfolio. Oakmont Corp is another notably bullish fund who is possessing 1.61M shares of DR Horton or 7.72% of their fund portfolio. In addition, Underhill Investment Management Llc have 5.36% of their fund portfolio invested in the company for 320,750 shares. The New York-based fund Sanders Capital Llc revealed it had acquired so far a stake worth about 4.99% of the fund’s stock portfolio in DR Horton. The Florida-based fund Dudley & Shanley Llc is also positive about the stock, possessing 20.93M shares or 4.41% of their fund portfolio.
DR Horton (NYSE:DHI) Profile
D.R. Horton, Inc. is a homebuilding company. The Company constructed and sold homes in 27 states and 79 markets, as of September 30, 2015.
DR Horton (NYSE:DHI) traded up 0.01% on 17 July, hitting $36.7. A total of shares of the company’s stock traded hands. This is down from average of 4.37M shares. DR Horton has a 52 week low of $26.69 and a 52 week high of $37.44. The company has a market cap of $13.86B and a P/E ratio of 14.28.
Get the latest DR Horton (NYSE:DHI) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.